Methods for predicting and monitoring spontaneous preterm birth - Patents.com

JP2025505035APending Publication Date: 2025-02-19INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024547469
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-02-10
Filing Date
2023-02-09
Publication Date
2025-02-19

Smart Images

  • Figure 2025505035000006
    Figure 2025505035000006
  • Figure 2025505035000007
    Figure 2025505035000007
  • Figure 2025505035000001
    Figure 2025505035000001
Patent Text Reader

Abstract

This is a prospective multicenter cohort study including 200 pregnant patients, with 5 serum samplings per patient. We investigated protein biomarker concentrations in the plasma of high-risk pregnant women in the second and third trimesters of pregnancy to predict spontaneous preterm birth. We showed that PROK1 (Prokineticin 1), also called EG-VEGF (endocrinoline-derived vascular endothelial growth factor), secreted by the placenta, was elevated in serum in sPTB patients less than 37 weeks pregnant compared to uncomplicated pregnant women. More precisely, women with spontaneous preterm birth showed higher serum PROK1 / EG-VEGF concentrations at 20, 24, 28 and 32 weeks than uncomplicated patients. Thus, serum PROK1 / EG-VEGF concentrations can be considered as biomarkers of spontaneous preterm birth in high-risk pregnant women.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Tools to predict risk of preterm birth

    JP2019512082A

  • Method for the early diagnosis of clinically latent placental insufficiency associated with defective placental maturation

    US20140249080A1